Anest. intenziv. Med. 2006;17(5):235-240

Administration of COX-2 inhibitors modifies the course of postoperative delirium in cardiac surgery patientsAnaesthesiology - Original Paper

M. Hála, P. Pavlík, R. Wagner
Centrum kardiovaskulární a transplantační chirurgie, Brno

Objective:
Postoperative delirium (POD) is a common complication after major surgery. Our aim was to prove the hypothesis that systemic inflammatory response syndrome (SIRS) contributes to the development of POD. SIRS is a complex network of mutually interacting processes where one of the terminal tissue effectors is COX-2.

Design:
Prospective open-label study.


Setting:
Center for Cardiac Surgery and Transplantation.

Materials and Methods:
86 consecutive patients all over 65 years of age with coronary artery disease were enrolled. All of them were indicated for open-heart surgery (with or without revascularization). Patients with a past history of postoperative delirium were excluded. The patients were randomized into two groups: treated (N = 40) and controls (N = 46). The treated patients were administered parecoxib (40 mg IV after arrival on the ICU + continuous infusion of 1 mg/kg/day on the day of surgery and the first postoperative day) followed by valdecoxib (2 x 20 mg orally) on the second and third days. Each postoperative day (1-7) the patients were scored for the severity and clinical relevance of POD (0-5). The incidence, duration and severity score of POD were evaluated.

Results:
No differences in age, comorbidity and perioperative factors were observed between the groups. The duration of POD was significantly shorter in the treated group than in the control group (1.9 ± 0.9 vs. 3.6 ± 1.6 days; P = 0.02). The incidence of POD was the same in both groups. The severity score was lower in the treated group but did not reach statistical significance. The difference in the incidence of postoperative complications was not significant.

Conclusion:
Systematic administration of COX-2 inhibitors shortened POD duration after cardiac surgery suggesting that COX-2 could contribute to its development. POD ranks among the complications induced by SIRS. Interventions targeted at suppressing SIRS could act as a prevention of POD.

Keywords: postoperative delirium; coxibs; cardiac surgery

Published: October 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hála M, Pavlík P, Wagner R. Administration of COX-2 inhibitors modifies the course of postoperative delirium in cardiac surgery patients. Anest. intenziv. Med. 2006;17(5):235-240.
Download citation

References

  1. Dyer, C. B., Ashton, C. M. Postoperative delirium - a review of 80 primary data-collection studies. Arch. Intern. Med.,1995, 155, p. 461-466. Go to original source... Go to PubMed...
  2. Laffey, J. G., Boylan, J. F., Cheng, D. C. H. The systemic inflammatory response to cardiac surgery. Anesthesiology, 2002, 97, p. 215-252. Go to original source... Go to PubMed...
  3. Bogatcheva, N. V., Sergeeva, M. G. Arachidonic acid cascade in endothelial pathobiology. Microvascular Research, 2005, 69, p. 107-127. Go to original source... Go to PubMed...
  4. Hála, M. Pooperační delirium - "častá" komplikace po kardiovaskulárních operacích (retrospektivní studie). Předneseno na 1. sjezdu České společnosti kardiovaskulární chirurgie 2004.
  5. Cernak, I., O'Connor, Ch., Vink, R. Inhibition of cyclooxygenase 2 by nimesulide improves cognitive outcome more than motor outcome following diffuse traumatic brain injury in rats. Experimental brain research, 2002, 147, p.193-199. Go to original source... Go to PubMed...
  6. Gierer, P., Mittlmeier, T. Selective cyclooxygenase-2 inhibition reverses microcirculatory and inflammatory sequelae of closed soft-tissue trauma in an animal model. Journal of bone and joint surgery, 2005, 87-A, p. 153-161. Go to original source...
  7. Song, A. M., Bhagat, L. Inhibition of cyclooxygenase-2 ameliorates the severity of pancreatitis and associated lung injury. American Journal of Physiology - Gastrointestinal and Liver Physiology, 2002, 283, p. 1166-1174. Go to original source... Go to PubMed...
  8. Cheruku, K. K., Ghani, A. Efficacy of nonsteroidal antiinflammatory medications for prevention of atrial fibrillation following coronary artery bypass graft surgery. Prev. Cardiol., 2004, Winter, 7 (1), p. 13-18. Go to original source... Go to PubMed...
  9. Nussmeier, N. A., Whelton, A. A. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. New England Journal of Medicine, 2005, 352, 11, p. 1081-1091. Go to original source... Go to PubMed...
  10. Ott, E., Nussmeier, N. A. Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. Journal of Thoracic and Cardiovascular Surgery, 2003, 125, 6, p. 1481-1492. Go to original source... Go to PubMed...
  11. Schneider, F., Bőhner, H. Risk factors for postoperative delirium in vascular surgery. General Hospital Psychiatry, 2002, 24, p. 28-34. Go to original source... Go to PubMed...
  12. Lynch, E. P., Lazor, M. A. The impact of postoperative pain on the development of postoperative delirium. Anesth. Analg., 1998, 86, p. 781-785. Go to original source...
  13. Silverstein, F. E., Faich, G. Gastrointestinal toxicity with celecoxib vs. nonsteroidal antiinflammatory drugs for osteoarthritis and rheumatoid arthritis. JAMA, 2000, 284, p. 1247-1255. Go to original source... Go to PubMed...
  14. Bombardier, C., Laine, L. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. New England Journal of Medicine, 2000, 343, 21, p. 1520-1528. Go to original source... Go to PubMed...
  15. Schnitzer, T. J., Burmester, G. R. Comparison of lumiracoxib with naproxen and ibuprofen in the therapeutic arthritis research and gastrointestinal event trial (TARGET). Lancet, 2004, Aug 21-27, 364, 9435, p. 665-674. Go to original source... Go to PubMed...
  16. Bresalier, R. S., Sandler, R. S. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. New England Journal of Medicine, 2005, 352, 11, p. 1092-1102. Go to original source... Go to PubMed...
  17. Solomon, S. D., McMurray, J. J. V. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. New England Journal of Medicine, 2005, 352, 11, p. 1071-1080. Go to original source... Go to PubMed...
  18. Hippisley-Cox, J., Coupland, C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ, 2005, 330, p. 1366-1372. Go to original source... Go to PubMed...
  19. Fosslien, E. Cardiovascular complications of non-steroidal anti-inflammatory drugs. Ann. Clin. Lab. Sci., 2005, 35, 4, p. 347-385.
  20. Bayindir, O., Akpinar, B. The use of the 5-HT3-receptor antagonist ondansetron for the treatment of postcardiotomy delirium. J. Cardiothorac Vasc. Anesth., 2000, 14, 3, p. 288-292. Go to original source... Go to PubMed...




Anesteziologie a intenzivní medicína

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.